Rheumatoid arthritis, lupus, fibromyalgia, Crohn's disease, and Sjögren's syndrome. Immune modulation is a core mechanism of MSC therapy — making autoimmune conditions a natural target.
Medical Disclaimer: Stem cell therapy for autoimmune conditions is not FDA or INVIMA-approved. Most clinical trials are Phase I–II. This treatment does not replace disease-modifying therapies prescribed by your rheumatologist or specialist. Always discuss with your physician before making changes to your treatment plan.
Autoimmune diseases occur when the immune system mistakenly attacks the body's own tissues. Conventional treatments typically suppress the immune system broadly (corticosteroids, immunosuppressants, biologics), which controls symptoms but comes with significant side effects including increased infection risk.
Mesenchymal stem cells work differently. Rather than broadly suppressing immunity, MSCs modulate the immune response — calming overactive components while supporting healthy immune function. This immunomodulatory mechanism is well-established in laboratory research and is the primary reason autoimmune conditions are a logical target for MSC therapy.
A 2025 global analysis of 244 autoimmune stem cell clinical trials (2006–2025) found that the majority (83.6%) were Phase I–II, focused primarily on Crohn's disease and systemic lupus erythematosus. The research field is growing rapidly, but definitive Phase III evidence remains limited for most conditions.
MSCs interact with the immune system in multiple ways: they suppress overactive T-cells, promote regulatory T-cells (which help prevent autoimmune attacks), reduce pro-inflammatory cytokines (IL-6, TNF-alpha, IL-17), and increase anti-inflammatory cytokines (IL-10, TGF-beta). This is not theoretical — these mechanisms are well-documented in laboratory and clinical settings. The question is whether a single MSC treatment course produces durable clinical improvement in autoimmune patients.
An autoimmune condition where the immune system attacks joint tissues. MSC therapy aims to modulate the immune attack while reducing joint inflammation. Some overlap with orthopedic protocols, since joints are the target — but the mechanism is different (immune modulation vs. tissue repair).
Moderate evidence • $8,500–$12,000Systemic lupus erythematosus causes widespread inflammation affecting skin, joints, kidneys, and other organs. MSC therapy has shown promising results in several clinical trials, particularly for patients who have not responded adequately to conventional immunosuppressive therapy.
Promising research • $10,000–$15,000Inflammatory bowel disease affecting the digestive tract. Crohn's is one of the most-studied autoimmune conditions for MSC therapy, with local injection for perianal fistulas showing particularly strong results. Darvadstrocel (Alofisel), an MSC-based product, was approved in the EU for this specific indication.
Stronger evidence (fistulas) • $10,000–$15,000Chronic widespread pain with possible autoimmune and neuroinflammatory components. Some patients report significant symptom relief after MSC therapy, though clinical trial data for fibromyalgia specifically is very limited. Results are highly variable.
Limited evidence • $8,500–$12,000An autoimmune condition primarily affecting moisture-producing glands, causing dry eyes and dry mouth. MSC therapy aims to modulate the immune attack on glandular tissue. Early clinical data is encouraging but limited to small studies.
Early evidence • $8,500–$12,000MS involves immune-mediated destruction of myelin in the nervous system. MS straddles both the autoimmune and neurological categories. For the neurological perspective, see our neurological conditions page.
Moderate evidence • $12,000–$20,000| Treatment | Colombia | US Price | Savings |
|---|---|---|---|
| Rheumatoid arthritis MSC protocol | $8,500–$12,000 | $20,000–$35,000 | 55–65% |
| Lupus (SLE) MSC protocol | $10,000–$15,000 | $25,000–$40,000 | 55–65% |
| Crohn's disease MSC protocol | $10,000–$15,000 | $25,000–$45,000 | 55–65% |
| General autoimmune protocol (IV) | $8,500–$12,000 | $20,000–$30,000 | 55–65% |
Prices estimated as of 2026. Autoimmune protocols may require repeat treatments at 6–12 month intervals for sustained benefit. Ask about booster pricing when evaluating total costs.
Autoimmune conditions are chronic — they do not go away. Stem cell therapy may reduce symptoms, decrease flare frequency, and potentially allow patients to reduce (but rarely eliminate) immunosuppressive medications. Here is what you should know:
Before pursuing stem cell therapy for any autoimmune condition, discuss it with your rheumatologist, gastroenterologist, or treating specialist. They need to know about any complementary treatments you are considering, and the stem cell clinic needs your complete medical history, including all current medications and their dosing.
For help understanding whether MSC therapy could complement your current autoimmune treatment plan, reach out for a free consultation.
Share your diagnosis, current medications, and what you are hoping to achieve. We will connect you with clinics experienced in autoimmune protocols.
Get Free Consultation